anmelden
OMX Stockholm 30
3.292,34
PKT
+34,01
PKT
+1,04
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu OMX Stockholm 30-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 09.03.18 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.03.18 | AstraZeneca Sell | Goldman Sachs Group Inc. | |
| 27.02.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 26.02.18 | ABB (Asea Brown Boveri) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 26.02.18 | AstraZeneca Hold | Jefferies & Company Inc. | |
| 21.02.18 | Volvo (B) buy | Deutsche Bank AG | |
| 21.02.18 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 19.02.18 | AstraZeneca Sell | Goldman Sachs Group Inc. | |
| 16.02.18 | ABB (Asea Brown Boveri) Underperform | Jefferies & Company Inc. | |
| 15.02.18 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 15.02.18 | Hennes Mauritz (H M, H&M) Underweight | JP Morgan Chase & Co. | |
| 15.02.18 | Hennes Mauritz (H M, H&M) verkaufen | Barclays Capital | |
| 14.02.18 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 12.02.18 | AstraZeneca Hold | S&P Capital IQ | |
| 12.02.18 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 09.02.18 | ABB (Asea Brown Boveri) overweight | Barclays Capital | |
| 09.02.18 | AstraZeneca Hold | S&P Capital IQ | |
| 09.02.18 | ABB (Asea Brown Boveri) buy | S&P Capital IQ | |
| 09.02.18 | ABB (Asea Brown Boveri) Equal-Weight | Morgan Stanley | |
| 08.02.18 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 08.02.18 | AstraZeneca buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 08.02.18 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 08.02.18 | ABB (Asea Brown Boveri) Conviction Buy List | Goldman Sachs Group Inc. | |
| 06.02.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 06.02.18 | AstraZeneca Neutral | UBS AG | |
| 06.02.18 | AstraZeneca buy | Deutsche Bank AG | |
| 06.02.18 | AstraZeneca buy | Kepler Cheuvreux | |
| 05.02.18 | Ericsson (Telefon L.M.Ericsson) (B) Underperform | Credit Suisse Group | |
| 05.02.18 | AstraZeneca Sell | Goldman Sachs Group Inc. | |
| 05.02.18 | Volvo (B) Neutral | JP Morgan Chase & Co. | |
| 05.02.18 | Ericsson (Telefon L.M.Ericsson) (B) Underperform | Merrill Lynch & Co., Inc. | |
| 05.02.18 | AstraZeneca buy | Deutsche Bank AG | |
| 05.02.18 | Volvo (B) Neutral | Goldman Sachs Group Inc. | |
| 02.02.18 | AstraZeneca overweight | JP Morgan Chase & Co. | |
| 02.02.18 | Ericsson (Telefon L.M.Ericsson) (B) Hold | Deutsche Bank AG | |
| 02.02.18 | Ericsson (Telefon L.M.Ericsson) (B) buy | Goldman Sachs Group Inc. | |
| 01.02.18 | Volvo (B) Underweight | Morgan Stanley | |
| 01.02.18 | Ericsson (Telefon L.M.Ericsson) (B) Neutral | UBS AG | |
| 01.02.18 | Volvo (B) Hold | Kepler Cheuvreux | |
| 01.02.18 | Ericsson (Telefon L.M.Ericsson) (B) Hold | Kepler Cheuvreux |
* Die angezeigten Realtime Kurse sind indikativ und nicht die offiziellen Börsenkurse. Die Kursdaten können eventuell vom tatsächlichen Marktpreis abweichen.
